Indeed, previous studies have confirmed that immunotherapy using immune checkpoint blockade, such as anti-PD-1 (Motzer et al., 2015, 2018) and anti-CTLA-4 (Motzer et al., 2018), to induce amplified endogenous anti-tumor T cell responses, has changed the clinical outcomes of ccRCC patients. The gene discussed is CTLA4; the disease is nonpapillary renal cell carcinoma.